Contrasting Charles River Laboratories International (NYSE:CRL) and IB Acquisition (NASDAQ:IBAC)

IB Acquisition (NASDAQ:IBAC) and Charles River Laboratories International (NYSE:CRL) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, earnings, dividends, analyst recommendations, institutional ownership, valuation and profitability.

Analyst Ratings

This is a breakdown of current ratings and price targets for IB Acquisition and Charles River Laboratories International, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IB Acquisition	1	0	0	0	1.00
Charles River Laboratories International	1	3	12	0	2.69

Charles River Laboratories International has a consensus target price of $255.65, indicating a potential downside of 12.39%. Given Charles River Laboratories International’s stronger consensus rating and higher possible upside, analysts clearly believe Charles River Laboratories International is more favorable than IB Acquisition.

Institutional & Insider Ownership

98.9% of Charles River Laboratories International shares are owned by institutional investors. 1.3% of Charles River Laboratories International shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares IB Acquisition and Charles River Laboratories International’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
IB Acquisition	N/A	N/A	N/A
Charles River Laboratories International	-5.96%	15.75%	6.51%

Valuation & Earnings

This table compares IB Acquisition and Charles River Laboratories International”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IB Acquisition	N/A	N/A	N/A	N/A	N/A
Charles River Laboratories International	$4.02 billion	3.47	-$144.34 million	($4.85)	-60.16

IB Acquisition has higher earnings, but lower revenue than Charles River Laboratories International.

Summary

Charles River Laboratories International beats IB Acquisition on 8 of the 9 factors compared between the two stocks.

About IB Acquisition

IB Acquisition Corp. is a blank check company. It formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or other similar business combination with one or more businesses or entities. IB Acquisition Corp. is based in Boca Raton, Florida.

About Charles River Laboratories International

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It also provides contract vivarium operation services to biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.